BioMedNewsBreaks Archive - Page 217 of 233

FridayOct 09, 2020 11:09 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"), has begun the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (“GBM”). GBM is an aggressive form of brain cancer currently considered incurable. “Our preparations for filing an IND for Berubicin require continued execution in both our clinical and manufacturing initiatives,” CNS Pharmaceuticals CEO John Climaco said in the news release. “With the manufacturing of our…

ThursdayOct 08, 2020 3:21 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report reads, “VistaGen is developing multiple therapeutic candidates for the treatment of anxiety, depression, and other CNS indications. VistaGen's development pipeline includes PH94B, a neuroactive nasal spray targeting Social Anxiety Disorder (‘SAD’), among other conditions, PH10, an additional neuroactive nasal spray for indications including Major Depressive Disorder (‘MDD’), and AV-101 an oral drug for psychiatric and other CNS disorders. We believe Phase 2 data in PH94B…

ThursdayOct 08, 2020 12:22 pm

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Announces Thailand Launch of My-Cardia ECG Product Line, Services

CB Scientific (OTC: CBSC), engaged in providing innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced the targeted start of cardiac lab services operations in the country of Thailand through CBSC’s exclusive authorized distributor, Mango Wellness Co. Ltd. (“MWC”) and My Cardia Thailand Co. Ltd. (“MCT”), beginning Oct. 29, 2020. Under the agreement, MWC and MCT will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is…

WednesdayOct 07, 2020 2:46 pm

BioMedNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Based out of South San Francisco, California, the “Birthplace of Biotechnology,” VistaGen is headquartered among the largest cluster of biotechnology companies in the world. A recent article discussing the company reads, “VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of…

WednesdayOct 07, 2020 12:03 pm

BioMedNewsBreaks – Marizyme Inc. (MRZM) Closes Acquisition of Somahlution Inc., $7M Private Placement

Marizyme (OTC: MRZM), a client of Univest Securities LLC, a full-service investment bank and securities broker-dealer firm and a member of FINRA and SIPC, recently closed the acquisition of Somahlution Inc. and a private placement for $7,000,240 to which Univest Securities acted as the exclusive investment bank and sole-placement agent. According to the update, the Marizyme acquisition of Somahlution Inc. included all of Somahlution LLC’s assets including its DuraGraft(R) intellectual property, Somaceutica intellectual property and derivative works. In addition, Univest Securities raised a total of $7,000,240 in gross proceeds in a private placement offering with common shares only for Marizyme,…

WednesdayOct 07, 2020 10:50 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO Scheduled to Present at LD Micro Event

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, is slated to present at an upcoming LD Micro virtual event. GNPX’s Zoom presentation is scheduled for Wednesday, Oct. 14, at 11 a.m. ET. The presentation will feature Genprex president and CEO Rodney Varner, who will deliver a corporate presentation and then participate in a Q&A. Investors and others interested in viewing the presentation can register at https://ibn.fm/MiDEy. To view the full press release, visit https://ibn.fm/RdBSZ About Genprex Inc. Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients…

WednesdayOct 07, 2020 10:22 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Closing of Public Offering

Processa Pharmaceuticals (NASDAQ: PCSA) has closed its previously announced underwritten public offering of 4,800,000 shares of common stock, which were offered to the public for $4 per share. The clinical-stage biopharmaceutical company, which focuses on the development of drug products intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment, announced that the public offering resulted in gross proceeds of approximately $19.2 million. PCSA has filed a registration statement relating to the securities being sold with the Securities and Exchange Commission (“SEC”);…

WednesdayOct 07, 2020 9:51 am

BioMedNewsBreaks – 180 Life Sciences Corp. Continues to Broaden Global IP Portfolio, Expand Internal Pipeline

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that has signed a detailed merger agreement with 180 Life Sciences Corp., a clinical-stage biotechnology company, on Tuesday announced continued expansion of 180 Life Sciences’ robust intellectual property (“IP”) portfolio. According to the update, 180 Life Sciences is an applicant and licensee of a broad and growing patent portfolio for three major drug platforms in the areas of inflammation, fibrosis and pain. The portfolio covers 14 patent families with 42 patents issued and 32 pending in several…

TuesdayOct 06, 2020 1:48 pm

BioMedNewsBreaks – Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (TASE: LCTX) Announces Broadening of Strategic Collaboration Regarding ESI Stem Cell Lines

Lineage Cell Therapeutics (NYSE American: LCTX) (TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, together with its subsidiary ES Cell International Pte Ltd. (“ESI”) and AgeX Therapeutics Inc. (NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, recently announced the broadening of their collaborative relationship regarding ESI stem cell lines. According to the update, ESI cell lines are current Good Manufacturing Practice (“cGMP”)-compatible, registered with the National Institutes of Health (“NIH”), and widely studied as a potential source for the industrial-scale manufacture of any cell type in the…

TuesdayOct 06, 2020 12:51 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable and even trending down, and revenues are stable and trending upward. The letter notes that POAI has adequate cash for operation, as well as ability to utilize an equity line of credit of more than $10 million. The letter also provides an update on the…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Announces Thailand Launch of My-Cardia ECG Product Line, Services

BioMedNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’

BioMedNewsBreaks – Marizyme Inc. (MRZM) Closes Acquisition of Somahlution Inc., $7M Private Placement

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO Scheduled to Present at LD Micro Event

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Closing of Public Offering

BioMedNewsBreaks – 180 Life Sciences Corp. Continues to Broaden Global IP Portfolio, Expand Internal Pipeline

BioMedNewsBreaks – Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (TASE: LCTX) Announces Broadening of Strategic Collaboration Regarding ESI Stem Cell Lines

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search